Monkeypox Vaccine and Treatment Market Sales and Revenues of Manufacturers Forecast till 2025-2032

Monkeypox Vaccine and Treatment Market size was estimated at USD 103.5 Mn in 2024 and the total Global Monkeypox Vaccine and Treatment revenue is projected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

Stellar Market Research published a report "Monkey pox Vaccine and Treatment Market and forecast (2025-2032)." The report is a comprehensive analysis of global monkey pox Vaccine and Treatment Market share, size, growth, trends, and forecast. The report also contains competitor analysis and regional analysis and gives attention to the recent market trend.

Access your sample copy of this report right now! https://www.stellarmr.com/report/req_sample/monkey-pox-vaccine-and-treatment-market/2670

The monkeypox vaccine and treatment market has increased dramatically with recent outbreaks and public health concerns, with well-known vaccines such as JYNNEOS and antiviral treatments like Tecovirimat leading the charge for the response. The pandemic has allowed for advances in vaccine technology and the emergence of public -private partnerships that are expanding the development and supply chain. Even with these advances, there is still innovation and collaboration that will be needed from all levels of society to increase the availability of prevention and treatment and respond to future outbreaks.

Monkeypox Vaccine and Treatment Market Dynamics

Rising Concern about Monkeypox Outbreak
The sudden re-emergence of monkeypox as a worldwide public health concern particularly due to the 2022 outbreak has led to a huge demand for vaccines and antiviral medication. Under-researched for decades in Africa, monkeypox is now found in non-endemic nations in Europe, North America, and Asia. There is, thus, a public health need for prompt and accessible medical countermeasures. The recurrence of monkeypox cases, combined with human international travel, and potential zoonotic reservoirs are producing sustained market demand.

Limited Availability and High Production Cost
Limited supply and high production costs are significant barriers in the monkeypox vaccine and treatment space. With small number of producers and inadequate specialized plants processing production of vaccines like JYNNEOS, global supply is scarce especially in outbreak situations. The cost of developing and producing both vaccines and antivirals like Tecovirimat limits broader access, particularly to low- and middle-income countries.

Expansion in Endemic and Underserved Regions
Much of Africa and Southeast Asia remain without sufficient access to monkeypox vaccines and treatments. Building surveillance, education, and immunization coverage in these environments is a massive business development opportunity and a chance for global health equity. Governments and NGOs increasingly finance activity to bridge the gap, which can stimulate long-term demand for low-cost solutions.

For additional insights into this study, please refer to: https://www.stellarmr.com/report/monkey-pox-vaccine-and-treatment-market/2670

Monkeypox Vaccine and Treatment Market Segment Analysis

✔Based on Product
The segment is comprised of vaccines and therapeutic drug (immunoglobulin). Vaccines occupy the lion's share (70% market share for vaccines) of the region marketplace, mainly due to their importance in outbreak prevention, and also that non-replicating vaccines like JYNNEOS are also extremely safer and more acceptable. Therapeutic products (ex; Tecovirimat) only apply to treatment (after infection), and the level of demand for these products is quite low when compared to vaccines primarily due to mass immunization.

✔Based on Route of Administration
The segment consists of oral and injectable routes. The oral route dominates the market, containing market share of more than 65% in 2024. Oral route therapeutics exhibit higher demand compared to injected products because they are easy to administer, and oral products are also economical. Nearly, all orally administered drugs such as brincidofovir and cidofovir.

Secure your sample copy of this report immediately! https://www.stellarmr.com/report/req_sample/monkey-pox-vaccine-and-treatment-market/2670

Monkeypox Vaccine and Treatment Market Regional Analysis
●North America
North America dominates the international market owing to aggressive government action, high expenditure on healthcare, and early regulatory clearance. The U.S. has taken a lead with strategic vaccine stockpiles such as JYNNEOS and extensive use of antivirals such as Tecovirimat. Good public health infrastructure and educative awareness have pushed mass vaccination and treatment campaigns ahead in this region, which is now the greatest contributor towards revenue from the market.

●Europe
Europe holds the second largest share in monkeypox vaccine and treatment market, supported by concerted response systems in organizations like the European Centre for Disease Prevention and Control (ECDC). Preventive vaccination campaigns have been launched by the UK, Germany, and France and they have gained access to valuable treatments. Increasing investments in research and public health readiness are likely to maintain growth within this region.

●Asia- Pacific
The Asia-Pacific stands in the third rank in the market due to increasing awareness, increased risk of contracting the infection, and government programs to strengthen epidemic preparedness. India, China, and Australia are enhancing surveillance systems and investment in health infrastructure. A huge population base and increasing availability of medical solutions propel market growth in the region.

●Middle East and Africa
Some of the nations within this region are endemic hotspots, inadequate health infrastructure, inadequate vaccine availability, and financing constraints have limited growth to low levels. Nevertheless, increased global emphasis on health equity and efforts by organizations like WHO to redistribute vaccines to under-served areas can improve the region's future market.

View Popular Topics Now :
✦Europe Exosome Research Market https://www.stellarmr.com/report/Europe-Exosome-Research-Market/826

✦Germany Ivf Services Market https://www.stellarmr.com/report/Germany-IVF-Services-Market/1587

Monkeypox Vaccine and Treatment Market Competitive Landscape
Bavarian Nordic: Being the developer of JYNNEOS, the sole FDA-approved non-replicating monkeypox vaccine, Bavarian Nordic has been at the forefront of global immunization. The company received a $156.8 million contract from the US government to manufacture further doses and is set to deliver up to 13 million doses by 2025.

SIGA Technologies: With its antiviral TPOXX (tecovirimat), SIGA has been heavily engaged in treating mpox. The company partnered with Oxford University to deliver tecovirimat for treating patients in the Central African Republic.

Recent Development
♦In 2024 Emergence of New Mpox Variant: A more deadly mpox variant emerged, specifically targeting children in Africa, with appeals to fast-track equitable vaccine distribution and enhanced international assistance.
♦2023 Broader Vaccine Indications: The European Medicines Agency (EMA) has advised a broader use of the smallpox vaccine IMVANEX for the prevention of mpox.

For more information, please contact:
Stellar Market Research:
S.no.8, h.no. 4-8 Pl.7/4, Kothrud,
Pinnac Memories Fl. No. 3, Kothrud, Pune,
Pune, Maharashtra, 411029
sales@stellarmr.com
+91 20 6630 3320, +91 9607365656

About Stellar Market Research:
Stellar Market Research is a global leader in market research and consulting services, specializing in a wide range of industries, including healthcare, technology, automobiles, electronics, and more. With a team of experts, Stellar Market Research provides data-driven market insights, strategic analysis, and competition evaluation to help businesses make informed decisions and achieve success in their respective industries.

This release was published on openPR.